UP!
|
Type
|
Public |
|---|---|
| Traded as | NASDAQ: ECYT |
| Industry | Biopharmaceutical |
| Founded | 1996 (1996) |
| Headquarters | West Lafayette, Indiana, United State |
|
Key people
|
Mike Sherman, President and CEO |
|
Number of employees
|
78 |
| Website | www |
Endocyte (NASDAQ: ECYT) is a biopharmaceutical company established in 1996 and headquartered in West Lafayette, Indiana, a resident of the Purdue Research Park. In 2011 the company completed successfully an initial public offering (IPO). As of 2013, the company had 93 employees. The original president and CEO, Ron Ellis, was succeeded by Mike Sherman, who held a CFO position at the company before this change in June 2016.
Endocyte is advancing the first technology platform for the creation of small molecule drug conjugates (a.k.a. SMDCs), which consist of a small molecule linked to a potent drug, and is developing a pipeline of SMDCs together with non-invasive companion imaging agents for cancer, inflammatory diseases and kidney disease (autosomal-dominant polycystic kidney disease/ADPKDor PKD). Endocyte’s lead drug candidate is vintafolide, an investigational targeted cancer therapeutic in late-stage development. In 2012 marketing rights were acquired by Merck for $120 million in an upfront payment and up to $880 million in milestone payments. Vintafolide is a small molecule drug conjugate consisting of a small molecule targeting the folate receptor, which is expressed on many cancers, such as ovarian cancer, and a potent chemotherapy drug, a derivative of vinblastine. Endocyte retained rights to the development and commercialization of etarfolatide.
Endocyte’s other preclinical drug candidates also target the folate receptor as well as prostate-specific membrane antigen (PSMA) receptors. The company was formed based on technology developed by Philip Low (the company's CSO), and Christopher Leamon, PhD, the company’s VP of research. This technology is a folic acid-based drug delivery system, referred to now as folate targeting. The company is also developing SMDCs with varying drug payloads as well as different ligands for other molecular targets, such as prostate-specific membrane antigen (PSMA) and has also developed, with Bristol-Myers Squibb, an epothilone-folic acid conjugate (BMS-753493), described at a 2008 conference.
| 2016-07-12 | Reiterated Rating | Credit Suisse Group AG | Buy | |
| 2016-05-04 | Reiterated Rating | Cowen and Company | Buy | |
| 2016-05-04 | Reiterated Rating | Wedbush | Outperform | $8.00 |
| 2016-03-07 | Reiterated Rating | Cowen and Company | Outperform | |
| 2016-03-02 | Reiterated Rating | Wedbush | Outperform | $12.00 to $8.00 |
| 2016-01-20 | Initiated Coverage | Credit Suisse | Outperform | $11.00 |
| 2016-01-20 | Initiated Coverage | Credit Suisse Group AG | Outperform | $11.00 |
| 2015-11-04 | Lower Price Target | RBC Capital | Outperform | $13.00 to $10.00 |
| 2015-11-04 | Lower Price Target | Royal Bank Of Canada | Outperform | $13.00 to $10.00 |
| 2015-09-08 | Reiterated Rating | Cantor Fitzgerald | Buy | $21.00 |
| 2015-08-05 | Lower Price Target | RBC Capital | Outperform | $15.00 to $13.00 |
| 2015-03-03 | Set Price Target | Wedbush | Buy | $12.00 |
| 2014-09-30 | Downgrade | Brean Capital | Buy to Hold | |
| 2014-09-29 | Reiterated Rating | Citigroup Inc. | Neutral | $8.00 to $10.00 |
| 2014-09-25 | Reiterated Rating | Chardan Capital | Positive | |
| 2014-09-08 | Initiated Coverage | Cantor Fitzgerald | Buy | $21.00 |
| 2014-07-30 | Reiterated Rating | Chardan Capital | Buy | |
| 2014-07-08 | Initiated Coverage | Brean Capital | Buy | $22.00 |
| 2014-06-18 | Reiterated | Chardan Capital Markets | Buy | $26 to $15 |
| 2014-06-18 | Lower Price Target | Chardan Capital | Buy | $26.00 to $15.00 |
| 2014-06-18 | Lower Price Target | RBC Capital | Outperform | $20.00 to $15.00 |
| 2014-06-05 | Initiated Coverage | Citigroup Inc. | Neutral | $8.00 |
| 2014-05-05 | Reiterated | Chardan Capital Markets | Buy | $43 to $26 |
| 2014-05-05 | Lower Price Target | Chardan Capital | Buy | $43.00 to $26.00 |
| 2014-05-05 | Lower Price Target | RBC Capital | Outperform | $46.00 to $20.00 |
| 2014-05-02 | Lower Price Target | Brean Capital | Buy | $41.00 to $22.00 |
| 2014-05-02 | Downgrade | Piper Jaffray | Overweight to Neutral | $13.50 |
| 2014-05-02 | Downgrade | Robert W. Baird | Outperform to Neutral | $36.00 to $8.00 |
| 2014-03-25 | Reiterated | Chardan Capital Markets | Buy | $20 to $43 |
| 2014-03-25 | Reiterated Rating | Wedbush | Outperform | $23.00 to $65.00 |
| 2014-03-25 | Boost Price Target | Chardan Capital | Buy | $20.00 to $43.00 |
| 2014-03-24 | Boost Price Target | Roth Capital | $20.00 to $42.00 | |
| 2014-03-21 | Boost Price Target | Brean Capital | Buy | $21.00 to $41.00 |
| 2014-03-21 | Boost Price Target | Piper Jaffray | Overweight | $17.00 to $36.00 |
| 2014-03-21 | Boost Price Target | Credit Suisse | Outperform | $24.00 to $44.00 |
| 2014-02-25 | Lower Price Target | Leerink Swann | $21.00 to $18.00 | |
| 2013-12-02 | Initiated Coverage | Piper Jaffray | Overweight | $17.00 |
| 2013-09-30 | Initiated | Chardan Capital Markets | Buy | $20 |
| 2013-09-30 | Initiated Coverage | Chardan Capital | Buy | $20.00 |
| 2013-09-16 | Initiated Coverage | Brean Capital | Buy | $21.00 |
| 2012-12-21 | Reiterated | RBC Capital Mkts | Outperform | $12 to $15 |
| 2012-11-20 | Initiated | Summer Street Research | Buy | $18 |
| 2011-03-17 | Initiated | RBC Capital Mkts | Outperform | $14 |
| 2016-07-12 | Reiterated Rating | Credit Suisse Group AG | Buy | |
| 2016-05-04 | Reiterated Rating | Cowen and Company | Buy | |
| 2016-05-04 | Reiterated Rating | Wedbush | Outperform | $8.00 |
| 2016-03-07 | Reiterated Rating | Cowen and Company | Outperform | |
| 2016-03-02 | Reiterated Rating | Wedbush | Outperform | $12.00 to $8.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In ECYT 9 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| BlackRock Fund Advisors | 1.28M |
| BlackRock Institutional Trust Company, N.A. | 0.52M |
| BlackRock Investment Management, LLC | 0.16M |
| KCG Holdings, Inc. | 47932 |
| Dynamic Technology Lab Pte Ltd | 24032 |
| BLACKROCK ADVISORS LLC | 21319 |
| ALPHAGEN SECURITIES LLC | 5600 |
| Li Winifred I | 1590 |
| MetLife Securities, Inc | 100 |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| Sherman Michael A. Chief Financial Officer | 0.91% (376064) | ECYT / MJN / |
| Low Philip S Chief Science Officer | 0.78% (326039) | ECYT / |
| Ellis P Ron President and CEO | 0.77% (320040) | ECYT / |
| MIDDLETON FRED A | 0.47% (197349) | CMRX / ECYT / PCRX / STXS / |
| Andriole Michael T. Chief Financial Officer | 0.36% (150000) | ECYT / |
| Leamon Christopher P Vice President of Research | 0.35% (143470) | ECYT / |
| Armour Alison A. Chief Medical Officer | 0.27% (111565) | ECYT / |
| Parker Katherine VP of Human Resources | 0.19% (77120) | ECYT / |
| Taylor Beth Corporate Controller | 0.17% (71540) | ECYT / |
| Chelius Erik C. Vice President CMC | 0.13% (54409) | ECYT / |
| Ritter Allen R VP of Manufacturing/CMC | 0.08% (34282) | ECYT / |
| APLIN JOHN C | 0.08% (32163) | ECYT / |
| Nguyen Binh VP of Clinical Affairs | 0.07% (28359) | ECYT / |
| Brinkley Michael A. VP OF QUALITY ASSURANCE | 0.06% (23486) | ECYT / |
| Harper Scot VP of CLINICAL OPERATIONS | 0.05% (22535) | ECYT / |
| BRAUER KEITH E | 0.04% (18271) | ECYT / |
| KOZIN MARC D | 0.03% (11100) | DYAX / ECYT / OVAS / UFPT / |
| GODDARD COLIN | 0.03% (11100) | ECYT / |
| Russell Lesley | 0.03% (11100) | AMAG / ECYT / ENTA / TLOG / |
| HANHAM ANN | 0.02% (7800) | ECYT / SCYX / |
| MELDRUM PETER D | 0.02% (7800) | ECYT / MYGN / |
| Meek David D. Chief Commercial Officer | 0.02% (7500) | ECYT / |
| Graham Dawn | 0.02% (7050) | ECYT / MDVN / PTCT / XENE / |
| Machado Clarence Patrick | 0.02% (7050) | AAVL / CMRX / ECYT / MDVN / SCYX / TKMR / |
| Lovejoy Chandra D VP of Regulatory Affairs | 0.02% (6250) | ECYT / |
UM